Crispr Therapeutics (CRSP) Announces Earnings Results

Share on StockTwits

Crispr Therapeutics (NASDAQ:CRSP) posted its quarterly earnings data on Thursday. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.33), Briefing.com reports. Crispr Therapeutics had a negative return on equity of 47.32% and a negative net margin of 331.84%. The business had revenue of $0.56 million during the quarter, compared to analyst estimates of $2.64 million. During the same period in the prior year, the firm posted ($0.62) EPS. Crispr Therapeutics’s revenue for the quarter was down 76.6% compared to the same quarter last year.

Shares of CRSP traded down $1.33 during trading hours on Friday, hitting $36.37. 539,024 shares of the stock traded hands, compared to its average volume of 950,146. Crispr Therapeutics has a 1-year low of $16.70 and a 1-year high of $73.90. The firm has a market capitalization of $1.83 billion, a PE ratio of -21.27 and a beta of 3.75.

A hedge fund recently raised its stake in Crispr Therapeutics stock. Bank of New York Mellon Corp boosted its stake in Crispr Therapeutics AG (NASDAQ:CRSP) by 42.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,104 shares of the company’s stock after purchasing an additional 9,326 shares during the quarter. Bank of New York Mellon Corp owned about 0.07% of Crispr Therapeutics worth $1,827,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 39.49% of the company’s stock.

Several brokerages have recently issued reports on CRSP. BidaskClub raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 3rd. Chardan Capital reaffirmed a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a research note on Wednesday, August 8th. Zacks Investment Research raised Crispr Therapeutics from a “hold” rating to a “strong-buy” rating and set a $42.00 price target on the stock in a research note on Tuesday, October 9th. Wells Fargo & Co began coverage on Crispr Therapeutics in a research note on Wednesday, October 10th. They set an “outperform” rating and a $65.00 price target on the stock. Finally, Raymond James began coverage on Crispr Therapeutics in a research note on Thursday, September 20th. They set an “underperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $62.47.

TRADEMARK VIOLATION NOTICE: “Crispr Therapeutics (CRSP) Announces Earnings Results” was first published by Week Herald and is owned by of Week Herald. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://weekherald.com/2018/11/10/crispr-therapeutics-crsp-announces-earnings-results.html.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

See Also: Benefits of owning preferred stock

Earnings History for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply